滤泡性淋巴瘤不良结局与MYC重排相关而非MYC额外拷贝
MYC额外拷贝对无进展生存和特定总生存无显著影响,而MYC重排与无进展生存、淋巴瘤相关死亡及转化风险的不良趋势相关。
要点
- MYC重排的滤泡性淋巴瘤患者年龄更大、FLIPI分期更高、β2微球蛋白更高。
- MYC额外拷贝对无进展生存和特定总生存无显著影响。
- MYC重排与无进展生存、淋巴瘤相关死亡和转化风险的不良趋势相关。
核心结论
- MYC额外拷贝在滤泡性淋巴瘤中无预后影响,而MYC重排倾向于与转化风险增加和更差结局相关。
研究设计与样本
- 回顾性研究纳入321例滤泡性淋巴瘤患者,其中259例(81%)无8q24改变,62例(19%)归为8qAlt。
主要发现
- 接受免疫化疗的患者中,4例为MYC重排,25例为MYC额外拷贝。
临床怎么用
- 对于滤泡性淋巴瘤患者,检测MYC重排可能有助于识别转化风险和预后不良的高危患者。
- MYC额外拷贝不应被视为预后不良的标志。
局限性
- 本研究为回顾性研究,样本量有限,尤其是MYC重排组仅6例。
- 部分结果基于与PRIMA试验数据的比较,非直接头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphomas (FLs) with MYC rearrangements (MYC-R) and extra copies of MYC (MYC-EC) are rare and the prognosis impact is uncertain. We conducted a retrospective study including 321 FL patients, among whom 259 (81%) had no 8q24 alterations and 62 (19%) were assigned to 8qAlt. Forty-five cases were classified as MYC-EC and six as MYC-R. MYC-R patients were significantly older (P = 0·008), had higher follicular lymphoma international prognostic index (FLIPI) stage (P = 0·05) and β2-microglobulin (β2m; P = 0·05). Among patients treated with immuno-chemotherapy, four presented a MYC-R and 25 a MYC-EC. Univariate analysis showed the absence of significant difference between MYC-EC and normal MYC (MYC-NL) regarding progression-free survival (PFS; HR1·3; 95% CI [0·4-1·6]) and specific overall survival (SOS; HR 1·6; 95% CI [0·4-5·7]). Those results were compared to data from the PRIMA trial. This confirmed that MYC-EC had no impact on PFS (P = 0·86) or SOS (P = 0·9). Conversely, MYC-R was associated with a trend to inferior outcome regarding PFS (HR : 6·1; 95% CI [2·2-17·1]; P = 0·00026), lymphoma-related death (SOS; HR 13·6; 95% CI [2·9-65]; P = 0·00014) and risk of transformation (transformation-free survival (TFS); HR 82·7; 95% CI [14·8-463·4]; P < 0·0001). In conclusion, MYC-EC has no prognostic impact in FL but MYC-R FL tended to be associated with an increased risk of transformation and poorer outcome.
引用
- Bussot L, Chevalier S, Cristante J, et al. Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies. Br J Haematol. 2021. PMID: 34155628. doi:10.1111/bjh.17550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。